MDGL — MADRIGAL PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1157601 ·
Last close
$421.99
Market Cap
$9.80B
52W High
$615.00
52W Low
$353.54
ADV30
506,542
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 431,268,000 393,453,000 55,989,000 55,442,000 1,434,389,000 514,642,000 807,448,000
Jun 2026 364,252,000 324,245,000 -56,308,000 -57,939,000 1,244,645,000 292,726,000 720,921,000
Mar 2026 311,337,000 284,490,000 -92,723,000 -94,391,000 1,227,327,000 227,033,000 683,873,000
Dec 2025 321,083,000 296,635,000 -59,609,000 -58,575,000 1,259,589,000 198,693,000 656,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-157,010,000
Investing CF
$347,758,000
Financing CF
$24,362,000
CapEx
$-12,030,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.98
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,187,354,000
Inventory
$122,589,000
Receivables
$227,377,000
ST Investments
$446,324,000
EBIT TTM
$-123,338,000
Pretax Income TTM
$-155,463,000
Interest Exp TTM
$32,125,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,427,939,968
EBITDA
$-151,100,992
Free Cash Flow
$-112,432,000
Enterprise Value
$8,676,480,000
Total Cash
$960,966,016
Total Debt
$354,216,992
Shares Out
23,229,561
Trailing EPS
$-5.85
Book Value
$27.00
ROE
-24.8%
ROA
-6.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 958,403,000 -300,097,000 -288,284,000 1,259,589,000 656,900,000 602,689,000 -189,553,000
Dec 2024 180,133,000 -497,875,000 -465,892,000 1,042,247,000 287,864,000 754,383,000 -455,572,000
Dec 2023 0 -380,496,000 -373,630,000 640,547,000 235,214,000 405,333,000 -324,230,000
Dec 2022 0 -293,571,000 -295,350,000 362,572,000 165,183,000 197,389,000 -224,857,000

TTM Snapshot

Revenues TTM
$1,283,940,000
NetIncome TTM
$-325,095,000
OpCashFlow TTM
—
Assets (Latest)
$1,244,645,000
Forward EPS
$11.21

Max Pain — expiry 2026-12-18

max pain strike: $500.00 · spot: $398.08 · call oi: 3,295 · put oi: 1,807
Expected Move to 2026-12-18: ±$49.55 (12.45%) — implied range $348.53 – $447.63 · ATM straddle on $400.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TGTX TG THERAPEUTICS, INC. $9.48B $62.71 —
SYRE Spyre Therapeutics, Inc. $8.91B $93.81 —
SMMT Summit Therapeutics Inc. $8.53B $10.67 —
PRAX Praxis Precision Medicines, Inc. $8.53B $305.06 —
BMRN BIOMARIN PHARMACEUTICAL INC $11.33B $58.51 —

News headlines (Yahoo Finance, 1h cache)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-11-18 21:04 · Yahoo
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
2026-11-13 13:00 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales
2026-11-05 17:25 · Yahoo
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
2026-11-05 15:00 · Yahoo
First Profitable Quarter Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL)
2026-11-04 23:17 · Yahoo
Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit
2026-11-04 18:11 · Yahoo
Madrigal Pharmaceuticals (MDGL) Turns Profitable, Is The 42% Undervaluation Case Still Convincing?
2026-11-04 03:22 · Yahoo
Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...
2026-11-03 21:05 · Yahoo
Madrigal (MDGL) Q3 2026 Earnings Call Transcript
2026-11-03 20:38 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.